Women’s Health: Link Between High Blood Pressure and Fibroids, and Risks of Second-Stage Cesarean Deliveries

by Ella

In the realm of women’s health, recent research has unveiled significant findings that shed light on the connection between high blood pressure and the development of uterine fibroids. Additionally, insights into the risks associated with second-stage cesarean deliveries have garnered attention.


Hypertension Medications May Mitigate Risk of Uterine Fibroids

New research, presented at the ASRM Scientific Congress & Expo, has underscored the association between untreated, new-onset hypertension and the heightened risk of developing uterine fibroids among midlife women. The study suggests that taking blood pressure medications to manage high blood pressure may play a pivotal role in reducing the risk of newly diagnosed fibroids.


Second-Stage Cesarean Deliveries and the Risk of Spontaneous Preterm Birth

A systematic review and meta-analysis have indicated that undergoing second-stage cesarean deliveries, particularly when mothers are at full cervix dilation, may increase the likelihood of subsequent spontaneous preterm birth compared to vaginal deliveries.


Obesity’s Link to Breast Cancer Recurrence

Another noteworthy revelation comes in the form of a link between obesity and an increased risk of breast cancer recurrence among postmenopausal women with hormone receptor-positive early-stage breast cancer. This association was identified in women who underwent treatment with aromatase inhibitors, as reported in JAMA Network Open.


Screening for Social Determinants of Health During Pregnancy

Despite the growing emphasis on social determinants of health, a study in the American Journal of Obstetrics and Gynecology reveals that fewer than half of hospitals participating in maternity care quality collaboratives systematically screen for these determinants during pregnancy. This highlights the need for more comprehensive approaches to maternal care.

Relugolix Combination Therapy Reduces Uterine Fibroid-Related Blood Loss

In a promising development, women who received relugolix combination therapy for 52 weeks and then discontinued the treatment continued to experience reduced menstrual blood loss and diminished pain attributed to uterine fibroids even after 2 years, according to researchers’ findings.

These recent advancements in women’s health research underscore the significance of addressing high blood pressure, pregnancy-related complications, obesity, and social determinants of health to ensure comprehensive care for women across various life stages.


You May Also Like

Womenhealthdomain is a professional women's health portal website, the main columns include women's mental health, reproductive health, healthy diet, beauty, health status, knowledge and news.

【Contact us: [email protected]

[email protected]

Call: 18066312111

© 2023 Copyright